The Diaz Lab integrates longitudinal patient specimens, single-cell and spatial genomics, genetic lineage tracing, machine learning, and functional models to identify mechanisms of treatment response and resistance—and convert them into biomarkers and therapeutic strategies.
Brain tumors are not static diseases. Their genetic clones, cellular states, and interactions with the brain and immune microenvironment change during therapy. These changes create resistance that is difficult to infer from a single biopsy or a single molecular assay. Our laboratory studies this evolution directly.
We combine longitudinal clinical specimens with single-cell and spatial multiomics, lineage tracing, computational modeling, and experimental validation. We aim to resolve which transitions are causal, which are clinically predictive, and which can be therapeutically targeted.
